Business
PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients
BOSTON, September 24, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, announced positive clinical data today from the 15 mg/kg dose cohort of its ongoing FREEDOM-DM1 Phase 1 single ascending dose (SAD) study in patients with myotonic dystrophy type 1 (DM1). These latest results demonstrated a mean splicing correction o
About this update from Pepgen Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/d3876c8a45e65e988814fdfef3f040a5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3othsOdosVi5vHYckOXXnA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d3876c8a45e65e988814fdfef3f040a5","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/6ngkpKYwcy8HXFsx39qUTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/d3876c8a45e65e988814fdfef3f040a5","width":1024,"height":512}},"lazy":false},{"type":"text","content":"– 53.7% mean splicing correction observed following a single 15 mg/kg dose of PGN-EDODM1, with all patients showing an improvement in splicing –","length":144,"tagName":"p","attribs":{}},{"type":"text","content":"– PGN-EDODM1 was generally well-tolerated at 15 mg/kg, with drug-related adverse events mild or moderate in severity –","length":118,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, September 24, 2025--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, announced positive clinical data today from the 15 mg/kg dose cohort of its ongoing FREEDOM-DM1 Phase 1 single ascending dose (SAD) study in patients with myotonic dystrophy type 1 (DM1). These latest results demonstrated a mean splicing correction of 53.7% following a single 15 mg/kg dose of PGN-EDODM1, substantially higher than any previously reported splicing correction in DM1 patients.","length":659,"tagName":"p"},{"type":"text","content":""We are delighted to report that the FREEDOM clinical study achieved all of its key objectives, including unprecedented splicing correction following a single dose of PGN-EDODM1 at 15 mg/kg," said Paul Streck, MD, MBA, Executive Vice President of Research and Development at PepGen. "Since mis-splicing is the underlying cause of DM1, we believe high levels of splicing correction have the potential to reverse the underlying molecular defects, and produce functional improvements in multiple out...